MAM
IOVA icon

Meeder Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Meeder Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-88
Closed -$1.3K – 914
2024
Q1 		$1.3K Buy
+88
New +$1.02K ﹤0.01% 724
2022
Q3 		– Sell
-14
Closed – – 2242
2022
Q2 		$0 Sell
14
-1,063
-99% -$13.9K ﹤0.01% 2303
2022
Q1 		$18K Buy
+1,077
New +$16.7K ﹤0.01% 1326
2021
Q2 		– Sell
-13,881
Closed -$439K – 2580
2021
Q1 		$439K Buy
+13,881
New +$575K 0.02% 525
2020
Q4 		– Sell
-6,288
Closed -$207K – 2036
2020
Q3 		$207K Sell
6,288
-1,741
-22% -$53.4K 0.01% 604
2020
Q2 		$220K Buy
8,029
+1,880
+31% +$61.8K 0.01% 578
2020
Q1 		$185K Sell
6,149
-1,885
-23% -$50K 0.01% 589
2019
Q4 		$223K Buy
8,034
+1,678
+26% +$38.2K 0.01% 572
2019
Q3 		$116K Buy
6,356
+5,207
+453% +$115K 0.01% 754
2019
Q2 		$29K Buy
1,149
+198
+21% +$2.98K ﹤0.01% 1115
2019
Q1 		$9K Sell
951
-99
-9% -$962 ﹤0.01% 1269
2018
Q4 		$9K Buy
1,050
+706
+205% +$6.81K ﹤0.01% 1275
2018
Q3 		$3K Sell
344
-1,068
-76% -$15.2K ﹤0.01% 1407
2018
Q2 		$18.1K Sell
1,412
-208
-13% -$3.04K ﹤0.01% 987
2018
Q1 		$28K Buy
1,620
+513
+46% +$7.77K ﹤0.01% 802
2017
Q4 		$9K Buy
1,107
+871
+369% +$6.99K ﹤0.01% 1151
2017
Q3 		$2K Sell
236
-1,489
-86% -$9.42K ﹤0.01% 1457
2017
Q2 		$13K Buy
1,725
+1,235
+252% +$7.85K ﹤0.01% 928
2017
Q1 		$4K Buy
+490
New +$3.59K ﹤0.01% 1163

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Meeder Asset Management's IOVA Position: Q2 2024 in Review

Meeder Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 88 shares — an estimated $1.3K sold.

Meeder Asset Management first reported a position in IOVA in Q1 2017 and held it in 19 quarters. The position peaked at $439K in Q1 2021. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • Meeder Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Meeder Asset Management sold 88 Iovance Biotherapeutics shares in Q2 2024, an estimated $1.3K.
  • Meeder Asset Management first reported a position in Iovance Biotherapeutics in Q1 2017 and held it in 19 quarters.
  • Meeder Asset Management's Iovance Biotherapeutics position peaked at $439K in Q1 2021.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on Meeder Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.